WILMINGTON, Del. An advisory committee of the Food and Drug Administration has given a mixed review to an approval application by AstraZeneca seeking additional uses for one of its drugs as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback